{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T15:51:21Z","timestamp":1753890681187,"version":"3.41.2"},"reference-count":17,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T00:00:00Z","timestamp":1655424000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Aims<\/jats:title><jats:p>Glucagon\u2010like peptide 1 (GLP-1) receptor agonists have demonstrated strong glycemic control. However, few studies have investigated the effects of switching from insulin to GLP-1 receptor agonists. We aimed to investigate, using real-world data, whether switching to dulaglutide improves glycemic control in patients with type 2 diabetes mellitus (T2D) inadequately controlled with conventional insulin treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and methods<\/jats:title><jats:p>We retrospectively evaluated 138 patients with T2D who were switched from insulin to dulaglutide therapy. We excluded 20 patients who dropped out during the follow-up period. The participants were divided into two groups according to whether they resumed insulin treatment at 6 months after switching to a GLP-1 receptor agonist (group I) or not (group II). A multiple logistic regression analysis was performed to evaluate the parameters associated with the risk of resuming insulin after replacement with dulaglutide.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of 118 patients initiated on the GLP-1 receptor agonist, 62 (53%) resumed insulin treatment (group I), and 53 (47%) continued with GLP-1 receptor agonists or switched to oral anti-hypoglycemic agents (group II). Older age, a higher insulin dose, and lower postprandial glucose levels while switching to the GLP-1 receptor agonist were associated with failure to switch to the GLP-1 receptor agonist from insulin.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>A considerable proportion of patients with T2D inadequately controlled with insulin treatment successfully switched to the GLP-1 receptor agonist. Younger age, a lower dose of insulin, and a higher baseline postprandial glucose level may be significant predictors of successful switching from insulin to GLP-1 receptor agonist therapy.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2022.880164","type":"journal-article","created":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T12:54:53Z","timestamp":1655470493000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Tolerability and Effectiveness of Switching to Dulaglutide in Patients With Type 2 Diabetes Inadequately Controlled With Insulin Therapy"],"prefix":"10.3389","volume":"13","author":[{"given":"Youngsook","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji Hye","family":"Huh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minyoung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eun Seok","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bong-Soo","family":"Cha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Byung-Wan","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,6,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)62154-6","article-title":"Pathophysiology and Treatment of Type 2 Diabetes: Perspectives on the Past, Present, and Future","volume":"383","author":"Kahn","year":"2014","journal-title":"Lancet"},{"key":"B2","article-title":"Clinical Inertia in Patients With T2DM Requiring Insulin in Family Practice","volume":"56","author":"Harris","year":"2010","journal-title":"Can Fam Physician"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.4093\/dmj.2021.0156","article-title":"2021 Clinical Practice Guidelines for Diabetes Mellitus of the Korean Diabetes Association","volume":"45","author":"Hur","year":"2021","journal-title":"Diabetes Metab J"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0905479","article-title":"Three-Year Efficacy of Complex Insulin Regimens in Type 2 Diabetes","volume":"361","author":"Holman","year":"2009","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.2337\/dc21-S009","article-title":"9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2021","volume":"44","year":"2021","journal-title":"Diabetes Care"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.4093\/dmj.2017.41.5.367","article-title":"Insulin Therapy for Adult Patients With Type 2 Diabetes Mellitus: A Position Statement of the Korean Diabetes Association, 2017","volume":"41","author":"Lee","year":"2017","journal-title":"Diabetes Metab J"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-005-0132-0","article-title":"Insulin Glargine or NPH Combined With Metformin in Type 2 Diabetes: The LANMET Study","volume":"49","author":"Yki-Jarvinen","year":"2006","journal-title":"Diabetologia"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.2337\/dcS15-3029","article-title":"When Intensive Insulin Therapy (MDI) Fails in Patients With Type 2 Diabetes: Switching to GLP-1 Receptor Agonist Versus Insulin Pump","author":"Cohen","year":"2016","journal-title":"Diabetes Care"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.2337\/db09-9028","article-title":"Banting Lecture. From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus","volume":"58","author":"Defronzo","year":"2009","journal-title":"Diabetes"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.4093\/dmj.2015.39.3.177","article-title":"The Role of Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes: Understanding How Data Can Inform Clinical Practice in Korea","volume":"39","author":"Oh","year":"2015","journal-title":"Diabetes Metab J"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.7326\/M20-0864","article-title":"Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes: A Systematic Review and Network Meta-Analysis","volume":"173","author":"Tsapas","year":"2020","journal-title":"Ann Intern Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.4093\/dmj.2020.0180","article-title":"Dulaglutide as an Effective Replacement for Prandial Insulin in Kidney Transplant Recipients With Type 2 Diabetes Mellitus: A Retrospective Review","volume":"45","author":"Kim","year":"2021","journal-title":"Diabetes Metab J"},{"key":"B13","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1016\/j.mcna.2004.04.013","article-title":"Pathogenesis of Type 2 Diabetes Mellitus","volume":"88","author":"DeFronzo","year":"2004","journal-title":"Med Clin North Am"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(19)30118-4","article-title":"Predicting Individual Treatment Response in Diabetes","volume":"7","author":"Heerspink","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2012.140","article-title":"GLP-1 Receptor Agonists for Individualized Treatment of Type 2 Diabetes Mellitus","volume":"8","author":"Meier","year":"2012","journal-title":"Nat Rev Endocrinol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.3466","article-title":"Switching From Insulin to Dulaglutide Therapy in Patients With Type 2 Diabetes: A Real-World Data Study","volume":"37","author":"Lee","year":"2021","journal-title":"Diabetes Metab Res Rev"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-2689","article-title":"Design of FLAT-SUGAR: Randomized Trial of Prandial Insulin Versus Prandial GLP-1 Receptor Agonist Together With Basal Insulin and Metformin for High-Risk Type 2 Diabetes","volume":"38","author":"Probstfield","year":"2015","journal-title":"Diabetes Care"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.880164\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T12:54:55Z","timestamp":1655470495000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.880164\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,17]]},"references-count":17,"alternative-id":["10.3389\/fendo.2022.880164"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2022.880164","relation":{},"ISSN":["1664-2392"],"issn-type":[{"type":"electronic","value":"1664-2392"}],"subject":[],"published":{"date-parts":[[2022,6,17]]},"article-number":"880164"}}